EMRIS Pharma
EMRIS Pharma

EMRIS Pharma

DR10Ahrefs DR: 10/100. Bottom 25%. Measured by Ahrefs. Median 44.Agent30Agent Readiness: 30/100. Below median. Measured by StartupHub.ai. Median 41.Speed78Site Speed: 78/100. Top 25%. Measured by Google PageSpeed. Median 62.Trust57Data Trust: 57/100. Below median. Measured by StartupHub.ai. Median 61.

Developing topical treatments to prevent and treat skin toxicities from cancer therapies.

2021Active7Tel Aviv, Israel

About

EMRIS Pharma is developing a first-in-class topical solution to prevent skin toxicities associated with targeted cancer therapies, particularly EGFR inhibitors. Their innovation aims to improve patients' quality of life and treatment compliance by blocking anti-cancer drugs in the skin without interfering with the therapy. This addresses the significant unmet need of severe skin side effects experienced by 80%-90% of patients treated with these drugs.

Key facts

At-a-glance profile data

Website
emris-pharma.com
Headquarters
Tel Aviv, Israel
Founded
2021
Employees
7
Total funding
-
Business model
B2B

Tech stack

Detected on emris-pharma.com, last scanned 15 Oct 2026.

Frontend
jQuery
SEO
Yoast SEO
CMS / Builders
WordPress
Email provider
Microsoft 365
Add first review

Frequently asked

Is EMRIS Pharma trustworthy and reputable?

StartupHub's Data Trust & Reputation score for EMRIS Pharma is 57 out of 100, a use-caution rating, based on site security posture, privacy practices, malware and phishing checks, and public reputation signals.

How many employees does EMRIS Pharma have?

EMRIS Pharma has approximately 7 people on record.